Loading…
OZEMPIC is a brand name for Semaglutide, supplied as a solution. The medicine, its uses, side effects and dosage are the same regardless of brand.
Verbatim from this product's HC label. Tap a section to expand.
). If cholelithiasis or cholecystitis are suspected, gallbladder studies and appropriate clinical follow-up are indicated. Immune Hypersensitivity Serious hypersensitivity reactions, including anaphylaxis, may occur with any GLP-1 receptor agonist, including OZEMPIC®.
If a hypersensitivity reaction occurs, the patient should discontinue OZEMPIC® and promptly seek medical advice. Do not use in patients with a previous hypersensitivity to OZEMPIC®. Caution should be exercised with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist because it is unknown whether such patients will be predisposed to anaphylaxis with OZEMPIC®.
Monitoring and Laboratory Tests Regular self-monitoring of blood glucose is not needed in order to adjust the dose of OZEMPIC®. However, when initiating treatment with OZEMPIC® in combination with a Product Monograph Ozempic® semaglutide injection Page 11 of 91 Unclassified / Non classifié sulfonylurea or insulin, blood glucose self-monitoring may become necessary to reduce the dose of the sulfonylurea or insulin in order to reduce the risk of hypoglycemia.
However, patients should be informed that response to all diabetic therapies should be monitored by periodic measurement of A1C levels, with a goal of decreasing these levels towards the normal range. A1C is especially useful for evaluating long-term glycemic control.
8%). The absolute risk increase for diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline than among patients without a known history of diabetic retinopathy. Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy.
Long-term glycemic control may decrease the risk of diabetic retinopathy. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy. Non-arteritic anterior ischaemic optic neuropathy (NAION) Data from epidemiological studies may indicate an increased risk of non-arteritic anterior ischaemic optic neuropathy (NAION) with a very rare frequency during treatment with semaglutide.
There is no identified time interval for when NAION may develop following treatment start. Patients reporting a sudden loss of vision (including partial loss) should be urgently referred for ophthalmological examination and treatment with semaglutide should be discontinued if NAION is confirmed.
Perioperative Considerations Aspiration in association with general anaesthesia or sedation OZEMPIC® delays gastric emptying. Pulmonary aspiration has been reported in patients receiving GLP-1 receptor agonists undergoing general anaesthesia or sedation.
This should be considered prior to such procedures. Renal Renal Insufficiency Use of GLP-1 receptor agonists may be associated with gastrointestinal adverse reactions. This should be considered when treating patients with impaired renal function as nausea, vomiting, and diarrhea, may cause dehydration which could cause a deterioration of renal function.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Semaglutide in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Monitor renal function in patients with renal insufficiency reporting severe adverse gastrointestinal reactions. See 8 Adverse Reactions. In patients treated with GLP-1 receptor agonists, there have been post-marketing reports of acute renal failure and worsening of chronic renal failure, which may sometimes require hemodialysis.
Some of these events were reported in patients without known underlying renal disease. A majority of reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration. Because these reactions may worsen renal function, use caution when initiating or escalating doses of OZEMPIC® in patients with renal impairment.
Product Monograph Ozempic® semaglutide injection Page 12 of 91 Unclassified / Non classifié Monitor renal function in patients with renal impairment reporting severe adverse gastrointestinal reactions. 1 Pregnancy Studies in animals have shown reproductive toxicity (see 16 Non-Clinical Toxicology).
No clinical trials in pregnant women have been conducted. Therefore, semaglutide should not be used during pregnancy. Women of childbearing potential are recommended to use contraception when treated with semaglutide. If a patient wishes to become pregnant, or pregnancy occurs, semaglutide should be discontinued.
Semaglutide should be discontinued at least 2 months before a planned pregnancy due to the long half-life. 3 Pharmacokinetics. 2 Breastfeeding It is not known whether OZEMPIC® is excreted in human milk. Semaglutide was present in the milk of lactating rats.
Because many drugs are excreted in human milk and the effects on the infant are unknown, OZEMPIC® should not be used for the duration of breastfeeding. 3 Pediatrics Safety and efficacy of OZEMPIC® have not been studied in pediatric patients.
OZEMPIC® is not indicated for patients with Type 2 Diabetes who are under 18 years of age. 3%) OZEMPIC®-treated patients were 75 years of age and above. 6%) OZEMPIC®-treated patients were 75 years of age and above. No overall differences in safety or efficacy were detected between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out due to limited data in geriatric patients.
2%) OZEMPIC®-treated patients had mild renal impairment (eGFR ≥60 […]